Abstracts tagged "Outcome measures"

Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Shahla Amin², Stephen Balevic³, Colleen Correll⁴, Timothy Beukelman¹ and , for the CARRA Registry Investigators⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, ³Duke University, Durham, NC, ⁴University of Minnesota, Minneapolis, MN, ⁵CARRA, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
Abstract Number: 1218 • ACR Convergence 2022
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
Philip J Mease¹, Alexis Ogdie², Dimitrios Pappas³, George Reed⁴ and Joel Kremer⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
Abstract Number: 1491 • ACR Convergence 2022
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
David Kiefer¹, Juergen Braun¹, Lucia Schneider¹, Niklas Kolle¹, Uta Kiltz¹, Ioana Andreica², Philipp Sewerin¹, Bjoern Buehring³, susanne herbold¹ and Xenofon Baraliakos⁴, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Bergisches Rheuma-Zentrum, Velbert, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
Abstract Number: 1902 • ACR Convergence 2022
Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials
Yusuf Yazici¹, Christopher Swearingen², Heli Ghandehari³, ismail simsek⁴, Sarah Kennedy⁵, Jeyanesh Tambiah⁶ and Timothy McAlindon⁷, ¹New York University School of Medicine, La Jolla, CA, ²Samumed LLC, San Diego, CA, ³Biosplice Therapeutics, Inc., San Diego, CA, ⁴Alpine Immunesciences, San Diego, CA, ⁵Biosplice Therapeutics, Inc, San Diego, CA, ⁶Biosplice Ther Inc., San Diego, CA, ⁷Tufts Medical Center, Arlington, MA
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability globally, and its disease burden is expected to increase as risk factors such as aging and…
Abstract Number: 2113 • ACR Convergence 2022
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
Dennis McGonagle¹, Derek Haaland², Philip Helliwell³, A. Marilise Marrache⁴, May Shawi⁵, Emmanouil Rampakakis⁶, Peter Nash⁷, Fedra Irazoque Palazuelos⁸ and Arthur Kavanaugh⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²The Waterside Clinic, Oro Medonte, ON, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷School of Medicine, Griffith University, Sunshine Coast, Australia, ⁸Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, ⁹University of California San Diego, La Jolla, CA
Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…
Abstract Number: 0611 • ACR Convergence 2021
Association of Area Deprivation Index and Practice Patterns of Medicare Part D Rheumatologists
Shannon Tai¹, Ikechukwu Mbonu² and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, West Allis, WI, ³Medical College of Wisconsin, Brookfield, WI
Background/Purpose: Geographic disparities in the distribution and practice patterns of rheumatology providers may negatively impact patients with rheumatic diseases. The objective of this study was…
Abstract Number: 0762 • ACR Convergence 2021
Validity of the Musculoskeletal Health Questionnaire: Real World Analysis of Data Collection via an Electronic Patient Reported Outcome Platform
Amy Boalch¹, Sam Norton¹, Sophia Steer², Nicky Wilson² and James Galloway³, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: The Musculoskeletal Health Questionnaire (MSK-HQ) is a patient reported outcome measure (PROM) validated to assess disease outcomes in patients with MSK disorders. This study…
Abstract Number: 1202 • ACR Convergence 2021
Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Gilles Boire⁵, Carol Hitchon⁶, Louis Bessette⁷, Diane Tin⁸, Edward Keystone⁹, Carter Thorne⁸, Janet Pope¹⁰ and Susan Bartlett³, ¹Hospital for Special Surgery, New York, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: During the COVID pandemic assessments of RA disease activity (DA) have relied on virtual assessments by patient report. It is unknown whether non-articular pain…
Abstract Number: 1615 • ACR Convergence 2021
Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis
Virginia Miraldi Utz¹, Amy Cassedy¹, Theresa Hennard¹, Najima Mwase² and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Children with uveitis often require topical eye medications (eye drops) to control inflammation (glucocorticoids) and complications such as elevated intraocular pressure and synechiae (glaucoma…
Abstract Number: 0085 • ACR Convergence 2021
Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
Naomi Patel¹, Kristin D'Silva¹, Tiffany Hsu², Michael Di Iorio³, Xiaoqing Fu¹, Claire Cook⁴, Lauren Prisco⁵, Lily Martin⁶, Kathleen Vanni⁶, Alessandra Zaccardelli⁶, Yuqing Zhang⁷, Jeffrey Sparks⁶ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with immune-mediated diseases have similar risk of severe COVID-19 versus the general population but CD20 inhibitor users may be at increased risk of…
Abstract Number: 0622 • ACR Convergence 2021
Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California
Kathleena D'Anna and Mehrnaz Hojjati, Loma Linda University Health, Loma Linda, CA
Background/Purpose: Giant-Cell Arteritis (GCA) is the most common systemic vasculitis among North Americans, historically described in Caucasian populations, with limited clinical data in other ethnic…
Abstract Number: 0763 • ACR Convergence 2021
What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset
Francesca Ridella¹, Roberta Naddei², Maddalena Spelta², Cristina N. Herrera³, Clara Malagon⁴, Olga Arguedas⁵, Amparo Ibanez Estrella⁶, Nicola Ruperto⁷, Angelo Ravelli⁸ and Alessandro Consolaro⁹, ¹Università degli Studi di Genova Genoa, Italy, Genova, Italy, ²Istituto Giannina Gaslini, Genova, Italy, ³Hospital de Ninos Roberto Gilbert Elizalde, Rheumatology, Guayaquil, Ecuador, Paediatric Rheumatology International Trials Organisation (PRINTO), Guayaquil, Ecuador, ⁴Hospital Universitario Simon Bolivar, Clinica infantil Colsubsidio, Facultad de Medicina, Post Grado Reumatologia Pediatrica, Universidad El Bosque, Bogota, Colombia, Paediatric Rheumatology International Trials Organisation (PRINTO), Bogotà, Colombia, ⁵Hospital Nacional de Ninos Dr Carlos Saenz Herrera, Servicio de Immunologia y Reumatologia pediatrica, San Josè, Costa Rica, Paediatric Rheumatology International Trials Organisation (PRINTO), San Josè, Costa Rica, ⁶National Institute Salud del Nino, Rheumatology Service, Brena, Lima, Peru, Paediatric Rheumatology International Trials Organisation (PRINTO), Lima, Peru, ⁷Istituto Giannina Gaslini, Paediatric Rheumatology International Trials Organisation (PRINTO), Genova, Italy, ⁸Istituto Giannina Gaslini, Genoa, Italy, ⁹Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: Parent- and child-reported outcomes (PCROs) reflect the parent and child perception of rheumatic disease course and effectiveness of therapeutic interventions. Among PCROs for the…
Abstract Number: 1203 • ACR Convergence 2021
A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Carol Hitchon⁵, Gilles Boire⁶, Diane Tin⁷, Louis Bessette⁸, Edward Keystone⁹, Carter Thorne⁷, Janet Pope¹⁰ and Susan Bartlett³, ¹Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Laval University, Québec City, QC, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: The Clinical Disease Activity Index (CDAI) is a frequently used composite measure by rheumatologists (MD) in routine care used to guide target-based treatment decisions.…
Abstract Number: 1674 • ACR Convergence 2021
Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Boulos Haraoui¹, Majed Khraishi², Denis Choquette¹, Larissa Lisnevskaia³, Michelle Teo⁴, Cassandra Kinch⁵, Corina Galos⁶, Patrice Roy⁵, David Gruben⁷, John C Woolcott⁸, Julie Vaillancourt⁹, John Sampalis¹⁰ and Edward Keystone¹¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada, ³Oshawa Clinic, Oshawa, ON, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Canada ULC, Kirkland, SK, Canada, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA, ⁹JSS Medical Research, Montréal, QC, Canada, ¹⁰McGill University and JSS Medical Research, Montréal, QC, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor (JAKi) for the treatment of RA. CANTORAL is the first large-scale, national, observational study assessing effectiveness and…
Abstract Number: 0129 • ACR Convergence 2021
Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker², Richard Bizier², Joseph Tkacz² and Robert Ortmann³, ¹AstraZeneca, Wilmington, DE, ²IBM Watson Health, Bethesda, MD, ³AstraZeneca, Greenwood, IN
Background/Purpose: The clinical presentation of systemic lupus erythematosus (SLE) is complicated, as patients cycle through periods of active disease (flares) and remission. To establish the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].